-
About UsBeijing Northland Biotechnology Co., Ltd. is an innovative biopharmaceutical company specializing in the research, development, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic drugs. -
R&DPrimarily dedicated to the research, development, and industrialization of novel bioengineered drugs in areas such as cardiovascular diseases, metabolic disorders, rare diseases, and ophthalmic diseases. -
Investor RelationsGuided by the principle of “Creating Value, Serving Health,” the company is committed to becoming an innovative biopharmaceutical enterprise, contributing to the advancement of China’s pharmaceutical industry and the well-being of humanity.
Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection (NL003)
【Drug Name】Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection
[Registration Category] Class 1 Therapeutic Biological Product (Gene Therapy Drug)
【Indications】Severe lower limb ischemic disease
[Specification and Dosage Form] 2 mg/1 mL/vial, aqueous injection
[Intellectual Property] Invention Patent
[Government Project] Major New Drug Discovery Initiatives under the National 11th and 13th Five-Year Plans
【R&D Progress】Phase III Clinical Study
[Registration Category] Class 1 Therapeutic Biological Product (Gene Therapy Drug)
【Indications】Severe lower limb ischemic disease
[Specification and Dosage Form] 2 mg/1 mL/vial, aqueous injection
[Intellectual Property] Invention Patent
[Government Project] Major New Drug Discovery Initiatives under the National 11th and 13th Five-Year Plans
【R&D Progress】Phase III Clinical Study
Recombinant Human Thymosin β4 for Injection (NL005)
【Drug Name】Recombinant Human Thymosin β4 (Tβ4) for Injection
[Registration Category] Class 1 Therapeutic Biological Product
【Indications】Ischemia-reperfusion injury caused by acute myocardial infarction
【Specifications and Dosage Form】 0.1 mg/vial, lyophilized powder for injection
[Intellectual Property] China, U.S., Europe, Japan, and South Korea Invention Patent/China Patent Excellence Award
[Government Project] National “Major New Drug Creation” Science and Technology Special Projects for the 11th, 12th, and 13th Five-Year Plans
【R&D Progress】Phase I completed, Phase II launched.
[Registration Category] Class 1 Therapeutic Biological Product
【Indications】Ischemia-reperfusion injury caused by acute myocardial infarction
【Specifications and Dosage Form】 0.1 mg/vial, lyophilized powder for injection
[Intellectual Property] China, U.S., Europe, Japan, and South Korea Invention Patent/China Patent Excellence Award
[Government Project] National “Major New Drug Creation” Science and Technology Special Projects for the 11th, 12th, and 13th Five-Year Plans
【R&D Progress】Phase I completed, Phase II launched.
Recombinant Human Modified Interleukin-11 for Injection (NL002)
【Drug Name】Recombinant Human Modified Interleukin-11 for Injection
[Registration Category] Biological Products for Therapeutic Use, Category 2
【Indications】Thrombocytopenia induced by tumor chemotherapy
[Specification and Dosage Form] 1.5 mg/vial, lyophilized powder for injection
[Intellectual Property] Chinese Invention Patent
[Government Project] National Major New Drug Creation under the 12th Five-Year Plan
【R&D Progress】Phase III Clinical Trial of the Drug
[Registration Category] Biological Products for Therapeutic Use, Category 2
【Indications】Thrombocytopenia induced by tumor chemotherapy
[Specification and Dosage Form] 1.5 mg/vial, lyophilized powder for injection
[Intellectual Property] Chinese Invention Patent
[Government Project] National Major New Drug Creation under the 12th Five-Year Plan
【R&D Progress】Phase III Clinical Trial of the Drug
Friendly Links: Baidu | NORTHLAND
Contact Information
Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing
Follow Us
Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.
Web site
NL-BIO
NL003
NL005